🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to researchers.

A Global Challenge

Gonorrhoea infections are increasing globally, with estimates suggesting in excess of 82 million instances each year. Notably increased rates are seen in Africa and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely step in the reality of rising global incidence, the spread of superbugs and the extremely scarce available drugs presently on offer.”

Health officials are particularly alarmed about the rise in drug-resistant strains. The global health body has designated it as a "high-priority threat". A tracking program revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Receive Approval

One new antibiotic, marketed under the name a brand name, was authorized by the US FDA in mid-December for treating gonorrhoea. This STI can lead to major issues, including infertility. Experts believe that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, originating from the drugmaker GSK, gained clearance in concurrent days. This drug, which is employed against urinary tract infections, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to bring it to fruition.

“This authorization represents a huge turning point in the treatment of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Research Study Outcomes and Global Access

According to results detailed in a major medical journal, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the typical regimen, which involves a dual-drug approach. The trial involved hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the ability to make available and distribute the drug in numerous low-income and middle-income countries.

Doctors treating patients have expressed hope. The availability of a one-pill regimen such as this is hailed as a "game-changer" for managing the epidemic. This is viewed as vital to alleviate the strain of the illness for people and to prevent the spread of untreatable gonorrhoea globally.